Ethan's Hope: "One day, no cancer"
Bringing light where there is none via cancer immunotherapy.
Most tumors are immunologically cold.
of patients do not respond to checkpoint inhibitors
of solid tumors are immunologically cold — excluded from all ICI benefit
of deaths from low-survival cancers occur within 1 year of diagnosis
global market value of the solution in 2026
LNP-siRNA target PP2A for immunotherapy resistant cancers.
PP2A-targeted siRNA-LNP. UCSF-validated science, strong IP position, built on exceptional brain tumor center infrastructure. Experienced founding team with research and clinical expertise.
Brain Cancer, Ovarian Cancer, Prostate Cancer, and Immunological Cold Tumors.
Having established proof of concept in pediatric brain cancer, glioblastoma, and ovarian cancer, our next step is expanding into prostate cancer and other immunologically cold, treatment-resistant cancers.
A patient story from Dr. Winson Ho’s practice
A 12-year-old Diffuse Intrinsic Pontine Glioma patient, asked if his tumor could be used for research that would not benefit him but could help other children, answered without hesitation:
“Yes, please! Please take more!”
